Senores Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	6,326	3,983	2,145	353.37	141.7
Other Revenue	470.6	-	-	-	-
Revenue	6,797	3,983	2,145	353.37	141.7
Revenue Growth (YoY)	70.67%	85.65%	507.07%	149.38%	-
Cost of Revenue	2,517	1,874	1,089	127.96	80.75
Gross Profit	4,280	2,108	1,057	225.41	60.95
Selling, General & Admin	1,123	636	363.1	51.75	28.92
Other Operating Expenses	1,004	575.1	277.5	46.93	12.51
Operating Expenses	2,439	1,380	740.8	116.47	48.48
Operating Income	1,841	728.8	315.8	108.94	12.47
Interest Expense	-250.3	-203.7	-85	-18.37	-5.1
Interest & Investment Income	-	71.6	4.6	0.39	1.93
Currency Exchange Gain (Loss)	-	34	10.7	34.21	2.68
Other Non Operating Income (Expenses)	10.1	75.2	3.6	-0.77	-0.55
EBT Excluding Unusual Items	1,601	705.9	249.7	124.4	11.43
Gain (Loss) on Sale of Assets	-	-0.2	-0.3	-0.03	-
Pretax Income	1,601	705.7	249.4	124.37	11.43
Income Tax Expense	375.7	122.3	-77.6	40.04	1.52
Earnings From Continuing Operations	1,225	583.4	327	84.33	9.91
Minority Interest in Earnings	-61.6	2.2	-12.5	-	-
Net Income	1,164	585.6	314.5	84.33	9.91
Net Income to Common	1,164	585.6	314.5	84.33	9.91
Net Income Growth	98.74%	86.20%	272.94%	750.96%	-
Shares Outstanding (Basic)	44	36	23	10	5
Shares Outstanding (Diluted)	44	36	26	13	5
Shares Change (YoY)	21.26%	41.13%	103.16%	131.33%	-
EPS (Basic)	26.39	16.10	13.67	8.87	1.81
EPS (Diluted)	26.39	16.10	12.21	6.65	1.81
EPS Growth	63.89%	31.88%	83.61%	267.92%	-
Free Cash Flow	-2,027	-2,034	-775.3	-483.56	-211.29
Free Cash Flow Per Share	-45.96	-55.94	-30.09	-38.12	-38.53
Gross Margin	62.97%	52.94%	49.25%	63.79%	43.01%
Operating Margin	27.09%	18.30%	14.72%	30.83%	8.80%
Profit Margin	17.12%	14.70%	14.66%	23.86%	6.99%
Free Cash Flow Margin	-29.82%	-51.08%	-36.14%	-136.84%	-149.11%
EBITDA	2,154	882.4	404.8	109.55	12.61
EBITDA Margin	31.69%	22.16%	18.87%	31.00%	8.90%
D&A For EBITDA	312.5	153.6	89	0.61	0.14
EBIT	1,841	728.8	315.8	108.94	12.47
EBIT Margin	27.09%	18.30%	14.72%	30.83%	8.80%
Effective Tax Rate	23.46%	17.33%	-	32.19%	13.30%
Revenue as Reported	6,797	4,175	2,173	390.21	146.31
Advertising Expenses	-	32.3	8.5	3.82	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.